Study Finds Weight‑loss Injections Associated With Large Drop in Hospital Admissions and Death Among Heart Failure Patients

A large real‑world analysis by US researchers found that people with heart failure who were obese and had type 2 diabetes and who received weight‑loss injections had substantially lower rates of death or hospital admission compared with similar patients who did not use the drugs.

Investigators at Mass General Brigham, a nonprofit hospital and physician network based in Boston, analyzed electronic health records for more than 90,000 patients with heart failure with preserved ejection fraction (HFpEF), the most common form of the condition. The team reported that use of semaglutide — sold under brand names including Ozempic and Wegovy — was associated with as much as a 58% lower risk of the combined outcome of death or hospitalization in this population relative to nonusers.

The study is described by its authors as the largest of its kind and draws on ‘‘real‑world’’ clinical data rather than a randomized controlled trial. Researchers said the findings add to growing evidence that incretin‑based therapies — drugs originally developed for diabetes that act on gut‑derived hormones to reduce appetite and blood sugar — may have cardiovascular benefits beyond weight loss and glucose control.

The report covers patients with obesity and type 2 diabetes who were diagnosed with HFpEF, a form of heart failure in which the heart contracts normally but does not relax properly between beats. Patients with HFpEF represent a large and growing share of heart‑failure cases, and treatment options have been limited.

Semaglutide is a glucagon‑like peptide‑1 (GLP‑1) receptor agonist. Other recent weight‑loss agents, such as tirzepatide (marketed as Mounjaro and Zepbound), act on both glucose‑dependent insulinotropic polypeptide (GIP) and GLP‑1 receptors and have shown strong effects on weight and metabolic measures. The Mass General Brigham analysis focused on semaglutide, but researchers and commentators have framed the results within broader interest in incretin‑based therapies for cardiovascular disease.

Investigators cautioned that the results are observational, meaning they show an association rather than definitive proof that the drugs caused the reduction in hospitalizations and deaths. The authors called for randomized controlled trials to confirm causality and to identify which patients with heart failure are most likely to benefit.

Experts have proposed several mechanisms by which these drugs might improve outcomes in heart‑failure patients, including weight loss, improved blood‑sugar control, lowered blood pressure, and direct effects on heart and blood‑vessel function. The relative contribution of each mechanism remains under study.

If confirmed in randomized trials, the findings could influence treatment guidelines and expand the population of patients considered for incretin‑based therapies. Such a shift would raise questions about access, cost, long‑term safety, and supply, as demand for these medicines has surged in recent years.

The analysis adds to a growing body of evidence that GLP‑1–based and related agents reduce cardiovascular risk in people with diabetes and obesity, but clinicians and policymakers will look to randomized trials and regulatory review before broadening indications. For patients with HFpEF — an area of unmet need — the new results are likely to prompt further investigation and discussion within the cardiology and endocrinology communities.